Shire plc (LSE: SHP, NASDAQ: SHPG) announces the acquisition of sanaplasma AG, a source plasma collection company headquartered in Switzerland.
sanaplasma AG is a privately-owned company focused on source plasma collection through its operation of 14 European plasmapheresis centres; 11 in the Czech Republic and three in Hungary.
The acquisition of sanaplasma AG is expected to increase Shire’s access to plasma in the longer term and add to its European plasma collection network, complementing existing core capabilities in plasma supply and manufacturing.
Plasma is essential to the manufacture of immunoglobulin therapies that help treat patients living with certain rare immunological diseases. Immunology is Shire’s largest franchise, with 18% growth on a pro-forma basis in 2017 to $4.4 billion in product sales, primarily driven by increased global demand for subcutaneous and intravenous immunoglobulin brands. This acquisition is expected to support the growth of the Immunology business and help meet the needs of patients around the world.
Bratschi Ltd. assisted the sellers in this transaction with a team included the partners Reto Arpagaus (picture) and Franz Szolansky as well as Silvia Renninger (senior associate) and Niklaus Glatthard (associate). Tax advice was provided by partner Michael Barrot.
Involved fees earner: Reto Arpagaus – Bratschi Wiederkehr & Buob Ltd.; Franz Szolansky – Bratschi Wiederkehr & Buob Ltd.; Silvia Renninger – Bratschi Wiederkehr & Buob Ltd.; Niklaus Glatthard – Bratschi Wiederkehr & Buob Ltd.; Michael Barrot – Bratschi Wiederkehr & Buob Ltd.;
Law Firms: Bratschi Wiederkehr & Buob Ltd.;